NMTC NEUROONE MEDICAL TECHNOLOGI...

Nasdaq n1mtc.com


$ 0.83 $ -0.04 (-4.43 %)    

Friday, 17-Oct-2025 15:59:39 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 0.825
$ 0.85
$ 0.80 x 1,500
$ 0.90 x 1,743
$ 0.81 - $ 0.86
$ 0.40 - $ 1.39
382,706
na
40.1M
$ 0.86
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 02-12-2025 12-31-2024 10-Q
4 12-17-2024 09-30-2024 10-K
5 08-14-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 02-13-2024 12-31-2023 10-Q
8 12-15-2023 09-30-2023 10-K
9 08-14-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 02-13-2023 12-31-2022 10-Q
12 12-22-2022 09-30-2022 10-K
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 02-14-2022 12-31-2021 10-Q
16 12-15-2021 09-30-2021 10-K
17 08-13-2021 06-30-2021 10-Q
18 05-14-2021 03-31-2021 10-Q
19 02-16-2021 12-31-2020 10-Q
20 12-09-2020 09-30-2020 10-K
21 08-13-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 02-14-2020 12-31-2019 10-Q
24 12-20-2019 09-30-2019 10-K
25 08-14-2019 06-30-2019 10-Q
26 05-10-2019 03-31-2019 10-Q
27 02-14-2019 12-31-2018 10-Q
28 08-13-2018 06-30-2018 10-Q
29 05-16-2018 03-31-2018 10-Q
30 04-16-2018 12-31-2017 10-K
31 11-14-2017 09-30-2017 10-Q
32 08-14-2017 06-30-2017 10-Q
33 05-22-2017 03-31-2017 10-Q
34 04-17-2017 12-31-2016 10-K
35 11-21-2016 09-30-2016 10-Q
36 08-19-2016 06-30-2016 10-Q
37 05-23-2016 03-31-2016 10-Q
38 04-14-2016 12-31-2015 10-K
39 11-16-2015 09-30-2015 10-Q
40 08-13-2015 06-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 neuroone-medical-technologies-reports-preliminary-fy25-results-of-91m-product-revenue-and-66m-cash-on-hand

 Preliminary Results On October 6, 2024, the Company reported the following preliminary unaudited fiscal year 2025 financial an...

 maxim-group-initiates-coverage-on-neuroone-medical-tech-with-buy-rating-announces-price-target-of-3

Maxim Group analyst Anthony Vendetti initiates coverage on NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy rating and announc...

 neuroone-medical-technologies--files-prospectus-for-675m-share-sale

-SEC Filing

 neuroone-medical-tech-affirms-fy2025-sales-guidance-of-800m-1000m-vs-871m-est

NeuroOne Medical Tech (NASDAQ:NMTC) affirms FY2025 sales outlook from $8.00 million-$10.00 million to $8.00 million-$10.00 mill...

 neuroone-medical-tech-q3-eps-003-beats-005-estimate-sales-170m-miss-182m-estimate

NeuroOne Medical Tech (NASDAQ:NMTC) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of...

 neuroone-medical-technologies-patient-treated-with-patented-onerf-ablation-system-surpasses-one-year-milestone-of-being-seizure-free

Patient Treated with OneRF® Ablation System Previously Experienced up to 10 Seizures a DayEDEN PRAIRIE, Minn., June 23, 2025 (G...

 neuroone-medical-tech-affirms-fy2025-product-revenue-guidance-of-800m-1000m

NeuroOne Medical Tech (NASDAQ:NMTC) affirms FY2025 sales outlook from $8.00 million-$10.00 million to $8.00 million-$10.00 mill...

 neuroone-medical-tech-q2-eps-007-up-from-011-yoy-sales-139m-beat-127m-estimate

NeuroOne Medical Tech (NASDAQ:NMTC) reported quarterly losses of $(0.07) per share. This is a 36.36 percent increase over losse...

 ladenburg-thalmann-initiates-coverage-on-neuroone-medical-tech-with-buy-rating-announces-price-target-of-145

Ladenburg Thalmann analyst Jeff Cohen initiates coverage on NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy rating and announ...

 neuroone-medical-technologies-files-510k-submission-to-fda-for-trigeminal-nerve-ablation-earlier-than-anticipated

Multi-Contact Probe Provides Alternative to Pharmaceutical and Invasive Surgical TreatmentsSubmission Completed Earlier Than An...

 neuroone-issues-letter-to-shareholders-reiterating-fy25-guidance-with-product-revenues-expected-to-increase-to-between-8m-10m-representing-an-increase-of-between-132-to-190-when-compared-to-product-revenue-of-35m-in-fy24

Today, we stand as a larger, more mature company than ever before as we ramp revenues and product margins. We have a world clas...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION